News Feature
Nature Biotechnology 26, 487 - 489 (2008)
doi:10.1038/nbt0508-487
The special treatment
Randy Osborne1
- Mill Valley, California
Abstract
The special protocol assessment introduced only six years ago by the US Food and Drug Administration (FDA) to facilitate clinical trials is gaining popularity. Randy Osborne finds out why.
